In contrast, the RCC viability was reduced to 50% in the anti-CAIX CAR T/anti-PD-L1 IgG1 group and 25% in the anti-PD-L1 IgG4 CAR T group, respectively. This evidence concerns the gene CD274 and renal cell carcinoma.